A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
Rodney S. Daniels, Ruth Harvey, Burcu Ermetal, Zheng Xiang, Mónica Galiano, Lorin Adams, John W. McCauley
Abstract
We describe a Sanger sequencing protocol for SARS-CoV-2 S-gene the Spike (S)-glycoprotein product of which, composed of receptor-binding (S1) and membrane fusion (S2) segments, is the target of vaccines used to combat COVID-19. The protocol can be used in laboratories with basic Sanger sequencing capabilities and allows rapid "at source" screening for SARS-CoV-2 variants, notably those of concern. The protocol has been applied for surveillance, with clinical specimens collected in either nucleic acid preservation lysis-mix or virus transport medium, and research involving cultured viruses, and can yield data of public health importance in a timely manner.